Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Baseline demographics of patients with and without concomitant memantine use

From: Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer’s disease: post-hoc analysis of a randomized placebo-controlled study

 

Memantine

No memantine

All

 

Placebo

Galantamine

Placebo

Galantamine

Memantine

No memantine

p value

N

245

251

776

773

496

1549

 

Sex

 Women (%)

60.4

67.3

65.2

64.9

63.9

65.1

0.7976χ

Age (years)

 Mean (SD)

74.2 (8.7)

73.8 (8.8)

72.8 (8.6)

72.7 (8.9)

74.0 (8.76)

72.8 (8.76)

0.008t

MMSE

 Mean (SD)

18.4 (4.2)

18.0 (4.1)

19.1 (4.0)

19.4 (4.1)

18.2 (4.16)

19.2 (4.02)

0.0001t

DAD

 Mean (SD)

59.0 (23.3)

57.0 (23.7)

61.5 (20.3)

63.4 (20.7)

58.0 (23.49)

62.5 (20.52)

0.0001t

AD duration (years)

 Mean (SD)

0.8 (1.3)

1.1 (1.7)

0.8 (1.7)

0.7 (1.3)

0.95 (1.50)

0.75 (1.57)

0.0127t

Prior therapy

 Cholinomimetic use (%)

23.3

23.5

16.0

13.3

23.4

14.7

0.0001χ

Nursing home placement

  N

116

101

312

305

217

617

 

 Cases, n (%)

10 (8.6)

3 (3.0)

14 (4.5)

13 (4.3)

13 (6.0)

27 (4.4)

0.3507χ

  1. χChi-square analysis
  2. t t test
  3. AD Alzheimer’s disease, DAD disability assessment for dementia, MMSE mini–mental state examination, SD standard deviation
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193